Momenta Pharmaceuticals, Inc. (MNTA) Insider Sells $62,445.00 in Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) insider Ian Fier sold 4,163 shares of the company’s stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $15.00, for a total transaction of $62,445.00. Following the completion of the transaction, the insider now directly owns 73,403 shares of the company’s stock, valued at approximately $1,101,045. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Ian Fier also recently made the following trade(s):

  • On Friday, March 15th, Ian Fier sold 10,000 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $13.92, for a total transaction of $139,200.00.

MNTA stock traded down $0.35 during mid-day trading on Thursday, hitting $14.41. The company had a trading volume of 279,610 shares, compared to its average volume of 609,983. The stock has a market cap of $1.41 billion, a P/E ratio of -7.08 and a beta of 2.23. Momenta Pharmaceuticals, Inc. has a 12-month low of $9.55 and a 12-month high of $32.20.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Friday, February 22nd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.39. The firm had revenue of $42.80 million for the quarter, compared to analysts’ expectations of $17.11 million. Momenta Pharmaceuticals had a negative net margin of 232.92% and a negative return on equity of 47.74%. The business’s revenue was down 33.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.18 EPS. On average, research analysts forecast that Momenta Pharmaceuticals, Inc. will post -1.72 EPS for the current fiscal year.

Several analysts have commented on MNTA shares. BTIG Research started coverage on shares of Momenta Pharmaceuticals in a research note on Monday, March 18th. They issued a “neutral” rating and a $14.15 price target on the stock. Zacks Investment Research cut shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 5th. BidaskClub upgraded shares of Momenta Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, January 18th. Stifel Nicolaus reiterated a “buy” rating and issued a $29.00 price target on shares of Momenta Pharmaceuticals in a research note on Friday, February 22nd. Finally, ValuEngine cut shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Momenta Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $22.03.

Several hedge funds and other institutional investors have recently made changes to their positions in MNTA. Wells Fargo & Company MN raised its position in shares of Momenta Pharmaceuticals by 3.8% during the 3rd quarter. Wells Fargo & Company MN now owns 236,651 shares of the biotechnology company’s stock valued at $6,224,000 after buying an additional 8,710 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Momenta Pharmaceuticals by 3.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 894,031 shares of the biotechnology company’s stock valued at $23,513,000 after buying an additional 27,708 shares in the last quarter. BlackRock Inc. raised its position in shares of Momenta Pharmaceuticals by 3.4% during the 3rd quarter. BlackRock Inc. now owns 12,080,344 shares of the biotechnology company’s stock valued at $317,713,000 after buying an additional 399,232 shares in the last quarter. Putnam Investments LLC purchased a new stake in shares of Momenta Pharmaceuticals during the 3rd quarter valued at about $6,706,000. Finally, MetLife Investment Advisors LLC raised its position in shares of Momenta Pharmaceuticals by 55.2% during the 3rd quarter. MetLife Investment Advisors LLC now owns 55,347 shares of the biotechnology company’s stock valued at $1,456,000 after buying an additional 19,674 shares in the last quarter. Hedge funds and other institutional investors own 96.88% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) Insider Sells $62,445.00 in Stock” was originally reported by WKRB News and is the property of of WKRB News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.wkrb13.com/2019/04/11/momenta-pharmaceuticals-inc-mnta-insider-sells-62445-00-in-stock.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Further Reading: Quick Ratio

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.